Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals develops, manufactures, and commercializes generic and proprietary injectable, inhalation, and intranasal medicines, as well as active pharmaceutical ingredient products. It sells prescription medicines and the over-the-counter product Primatene MIST®. Its marketed products include BAQSIMI® glucagon nasal powder, glucagon and epinephrine injections, naloxone products, and inhalers. It also sells recombinant human insulin and porcine insulin APIs, including to third parties. Amphastar makes money by selling medicines and APIs to hospitals, long-term care facilities, clinics, doctors’ offices, retail pharmacies, and other customers. The company develops generic, biosimilar, and proprietary product candidates and has capabilities spanning research and development, API production, manufacturing, and commercialization. Its manufacturing facilities are in Rancho Cucamonga and South El Monte, California; Canton, Massachusetts; Éragny-sur-Epte, France; and Nanjing, China. Amphastar is headquartered in Rancho Cucamonga, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AMPH in the last 30 days.
See all $AMPH insider activity →Wells Fargo kept Amphastar Pharma at Equal-Weight, raising its price target to $25 from $20, suggesting a 9.6% downside from the Nov 5 close of $27.66.
Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.6M, up 8% YoY, with adjusted EPS of $1.14. CFO Bill Peters addressed pricing headwinds, IMS remediation costs, and growth drivers like Baximi and Primatene Mist. The company expects continued lidocaine demand but constrained capacity. Insulin biosimilar launches are planned for 2027, with margin normalization dependent on higher volumes. Q4 sales are expected to grow in the high single digits.
Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.61M, up 8.2% YoY, and net income of $37.76M, up 117.7% YoY. Growth in BAQSIMI, Primatene MIST, and lidocaine sales offset declines in epinephrine and glucagon. New ipratropium bromide sales contributed $6.6M. Lower expenses also boosted income.
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning AMPH (Amphastar Pharmaceuticals, Inc.). Coverage has skewed bullish: 8 bullish, 2 neutral, and 1 bearish.
Recent AMPH coverage spans earnings, financial news and insider activity.
Analyst upgrade with a lower price target suggests the stock may face selling pressure.
Record revenue and a fresh buyback tranche suggest upside, but pricing headwinds may limit gains.
Strong earnings beat with higher revenue and EPS suggest upside pressure.
Strong short-term rally from earnings surprise.
Insider sale by a senior executive may signal weak confidence, but the amount is modest.
AlphAI scores every news story that mentions AMPH with an AI model for sentiment and relevance, and aggregates insider trades from Amphastar Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo kept Amphastar Pharma at Equal-Weight, raising its price target to $25 from $20, suggesting a 9.6% downside from the Nov 5 close of $27.66.
Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.6M, up 8% YoY, with adjusted EPS of $1.14. CFO Bill Peters addressed pricing headwinds, IMS remediation costs, and growth drivers like Baximi and Primatene Mist. The company expects continued lidocaine demand but constrained capacity. Insulin biosimilar launches are planned for 2027, with margin normalization dependent on higher volumes. Q4 sales are expected to grow in the high single digits.
Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.61M, up 8.2% YoY, and net income of $37.76M, up 117.7% YoY. Growth in BAQSIMI, Primatene MIST, and lidocaine sales offset declines in epinephrine and glucagon. New ipratropium bromide sales contributed $6.6M. Lower expenses also boosted income.
Viatris (VTRS), Amphastar (AMPH), ANI Pharmaceuticals (ANIP), and Amneal (AMRX) reported Q2 earnings. VTRS revenue grew 4.9% YoY, beating estimates. AMPH saw 5.4% growth, ANIP 25.9%, and AMRX 9.9%. Stocks reacted positively except ANIP, which fell 12%.
Zhou Rong (SENIOR EVP, PRODUCTION CENTER) sold 10,000 shares of Amphastar Pharmaceuticals, Inc. (AMPH) at $23.94 ($0.24M total) on 2026-09-16.
Amphastar Pharmaceuticals (AMPH) VP Rong Zhou plans to sell 10,000 shares, including 10,000 from an option exercise and smaller lots from the ESPP. The sale is under Rule 144, with UBS Financial Services acting as attorney-in-fact. The largest block is 10,000 shares.
Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
Amphastar Pharmaceuticals (AMPH) insider Floyd Petersen plans to sell 47,101 shares, worth $989,121, via UBS. The shares were acquired through option exercise, with the sale proposed for August 18, 2026. Amphastar has 44.1 million shares outstanding. The sale is under SEC Rule 144, which governs insider share sales.
A peer comparison of Q2 results in generic pharmaceuticals says the four tracked companies beat analysts’ revenue consensus by 2.6% on average, but shares fell 5.6% since reporting. ANI Pharmaceuticals (ANIP) revenue was $266m (+25.9%), EPS beat, but full-year revenue guidance missed; stock down 9.1% to $75.12. Amphastar (AMPH) revenue $183.9m (+5.4%) beat; stock up 2.3% to $20.28. Viatris (VTRS) revenue $3.76b (+4.9%) beat; stock down 7.6% to $16.32. Amneal (AMRX) revenue $796.2m (+9.9%) beat;
Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.
